Opinion|Videos|November 13, 2025
The Value of Subcutaneous Therapy for Patients
Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.
Advertisement
Episodes in this series
Panelists discuss how subcutaneous (SC) delivery is transforming oncology care by improving efficiency and patient convenience. They outline how SC formulations reduce infusion chair time, streamline scheduling, and ease strain on health care resources amid workforce shortages. The discussion underscores that SC administration enhances patient satisfaction through shorter visits and less invasive care while providing operational benefits for clinics. SC formulations are positioned as a modern solution for balancing clinical outcomes with system-wide efficiency.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
4
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
5